A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Summary
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | — |
| Subject | Dabrafenib | Small molecule | — | — |
| Subject | Entrectinib | Small molecule | — | — |
| Subject | Larotrectinib | Small molecule | — | — |
| Subject | Lenvatinib | Small molecule | — | — |
| Subject | Pralsetinib | Small molecule | — | — |
| Subject | Selpercatinib | Small molecule | — | — |
| Subject | Trametinib | Small molecule | — | — |
Indications
No indication recorded.